Bintai Kinden managing director Ong Choon Lui expects the collaboration between Generex and its China partners to advance the li-Key vaccine development platform.
KUALA LUMPUR: Bintai Kinden
Bhd's partner Generex Biotechnology Corporation has signed a US$50mil licensing and development deal for its Ii-Key vaccine platform technology.
It said on Thursday the agreement, which was signed with its partners in China, was for the technology provided by Generex’s subsidiary NuGenerex Immuno-Oncology Inc.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
